Abagovomab: An anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer Review uri icon

Overview

MeSH Major

  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • CA-125 Antigen
  • Ovarian Neoplasms

abstract

  • Ovarian cancer remains the leading cause of death due to gynecologic malignancies. Most patients present with advanced disease at the time of diagnosis. Although many have a good initial response to surgical debulking and platinum-based chemotherapy, relapse is common, with the eventual development of chemotherapy resistance. Innovative treatments are needed in the remission setting to prolong the disease-free interval or prevent recurrence. Abagovomab is a murine monoclonal anti-idiotypic antibody (molecular weight: 165-175 kDa) that functionally imitates the tumor-associated antigen, CA-125. It has been shown to be well tolerated and to induce a sustained immune response in initial Phase I and II clinical trials. An ongoing, double-blind, placebo-controlled, multicenter, Phase III trial (MIMOSA) completed its double-blind period in December 2010 and will compare abagovomab maintenance therapy to placebo, which will definitively determine the efficacy of this immunotherapeutic approach in patients with ovarian cancer.

publication date

  • February 2011

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC3221001

Digital Object Identifier (DOI)

  • 10.2217/imt.10.100

PubMed ID

  • 21322756

Additional Document Info

start page

  • 153

end page

  • 62

volume

  • 3

number

  • 2